Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

<h4>Objective</h4>To estimate the lifetime cost utility of two antiretroviral regimens (once-daily atazanavir plus ritonavir [ATV+r] versus twice-daily lopinavir/ritonavir [LPV/r]) in Italian human immunodeficiency virus (HIV)-infected patients naïve to treatment.<h4>Design</h4&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Emanuela Foglia, Paolo Bonfanti, Giuliano Rizzardini, Erminio Bonizzoni, Umberto Restelli, Elena Ricci, Emanuele Porazzi, Francesca Scolari, Davide Croce
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/6e465ad2763a4b9cabc456a5ad1e531a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares